CGS 125
Alternative Names: CGS-125; trans-capsaicin - CapGenesis TherapeuticsLatest Information Update: 28 Oct 2021
Price :
$50 *
At a glance
- Originator CapGenesis Therapeutics
- Class Analgesics; Antipruritics; Catechols; Local anaesthetics; Monounsaturated fatty acids; Non-opioid analgesics; Polyunsaturated alkamides; Small molecules
- Mechanism of Action TRPV1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Osteoarthritis
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for clinical-Phase-Unknown development in Osteoarthritis in Dominican Republic (Topical)
- 23 Nov 2015 Clinical trials in Osteoarthritis in Dominican Republic (Topical)